T1	CHEM 95 106	gevokizumab
#1	AnnotatorNotes T1	C3179523; gevokizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	PROC 44 77	Estudio para evaluar la seguridad
T3	DISO 124 153	uveítis crónica no infecciosa
T4	PROC 223 268	Estudio de extensión en abierto, de seguridad
T5	PROC 290 301	tratamiento
#2	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	DISO 319 348	uveítis crónica no infecciosa
T7	CHEM 272 283	Gevokizumab
#3	AnnotatorNotes T7	C3179523; gevokizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	DISO 392 421	Uveítis crónica no infecciosa
T9	PROC 609 626	doble enmascarado
T10	PROC 711 728	doble enmascarado
T11	CHEM 822 833	gevokizumab
#4	AnnotatorNotes T11	C3179523; gevokizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T12	CHEM 948 959	gevokizumab
#5	AnnotatorNotes T12	C3179523; gevokizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	CHEM 1020 1048	medicamento en investigación
#6	AnnotatorNotes T13	C0013230; Investigational New Drugs; Pharmacologic Substance
T14	CHEM 190 201	gevokizumab
#7	AnnotatorNotes T14	C3179523; gevokizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T15	CHEM 1114 1142	medicamento en investigación
#8	AnnotatorNotes T15	C0013230; Investigational New Drugs; Pharmacologic Substance
T16	PROC 1378 1399	método anticonceptivo
#9	AnnotatorNotes T16	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T17	CHEM 1542 1553	gevokizumab
#10	AnnotatorNotes T17	C3179523; gevokizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T18	DISO 1530 1537	uveítis
#11	AnnotatorNotes T18	C0042164; Uveitis; Disease or Syndrome
T19	DISO 1556 1574	Uveítis infecciosa
T20	DISO 1577 1596	síndromes mascarada
#12	AnnotatorNotes T20	C1444690; Masquerade syndrome; Disease or Syndrome
T21	DISO 1615 1622	alergia
#13	AnnotatorNotes T21	C1527304; Allergic Reaction; Pathologic Function
T22	DISO 1631 1652	reacción anafiláctica
#14	AnnotatorNotes T22	C0002792; anaphylaxis; Disease or Syndrome
T23	CHEM 1677 1705	medicamento en investigación
#15	AnnotatorNotes T23	C0013230; Investigational New Drugs; Pharmacologic Substance
T24	CHEM 1765 1776	excipientes
#16	AnnotatorNotes T24	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T25	DISO 1779 1800	Enfermedad infecciosa
#17	AnnotatorNotes T25	C0009450; Communicable Diseases; Disease or Syndrome
T26	DISO 894 901	uveítis
#18	AnnotatorNotes T26	C0042164; Uveitis; Disease or Syndrome
T27	PROC 935 944	inyección
#19	AnnotatorNotes T27	C1533685; Injection procedure; Therapeutic or Preventive Procedure
T28	PROC 1001 1015	administración
#20	AnnotatorNotes T28	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T29	PROC 1095 1109	administración
#21	AnnotatorNotes T29	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T30	CHEM 1735 1746	gevokizumab
#22	AnnotatorNotes T30	C3179523; gevokizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T31	PROC 1658 1672	administración
#23	AnnotatorNotes T31	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T32	Date 12 16	2013
T33	Date 78 91	a largo plazo
T34	LIVB 110 119	pacientes
#24	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T35	Duration 132 139	crónica
#25	AnnotatorNotes T35	C0205191; chronic; Temporal Concept
T37	LIVB 305 314	pacientes
#26	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	Duration 327 334	crónica
#27	AnnotatorNotes T38	C0205191; chronic; Temporal Concept
T40	Duration 400 407	crónica
#28	AnnotatorNotes T40	C0205191; chronic; Temporal Concept
T42	LIVB 459 464	mujer
#29	AnnotatorNotes T42	C0043210; Woman; Population Group
T43	Age 471 494	mayor o igual a 18 años
T46	Duration 963 976	las 6 semanas
T47	Duration 1170 1190	superior a 6 semanas
T48	LIVB 1222 1231	pacientes
#30	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T49	LIVB 1292 1304	investigador
#31	AnnotatorNotes T49	C0035173; Research Personnel; Professional or Occupational Group
T50	LIVB 1313 1349	pacientes con potencial reproductivo
T36	Age 498 519	mayoría de edad legal
T39	LIVB 450 456	Hombre
#32	AnnotatorNotes T39	C0025266; Male population group; Population Group
T41	PROC 628 634	visita
#33	AnnotatorNotes T41	C1512346; Patient Visit; Health Care Activity
T44	PROC 527 546	visita de selección
#34	AnnotatorNotes T44	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T45	PROC 1198 1217	visita de inclusión
#35	AnnotatorNotes T45	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T51	Quantifier_or_Qualifier 635 639	F000
A1	Status T14 History_of
A2	Status T9 History_of
A3	Status T10 History_of
A4	Status T17 History_of
A5	Status T21 History_of
A6	Status T22 History_of
A7	Status T31 History_of
A8	Status T23 History_of
A9	Status T30 History_of
A10	Status T24 History_of
#36	AnnotatorNotes T33	C0443252; Long-term; Temporal Concept
#37	AnnotatorNotes T2	C1705187; Safety Study; Research Activity
#38	AnnotatorNotes T9	C0013072; Double-Blind Method; Research Activity
#39	AnnotatorNotes T10	C0013072; Double-Blind Method; Research Activity
T52	Spec_cue 1327 1336	potencial
T53	PHYS 1337 1349	reproductivo
A11	Assertion T53 Speculated
#40	AnnotatorNotes T53	C0232896; Reproductive function; Physiologic Function
R1	Speculation Arg1:T52 Arg2:T53	
T54	Quantifier_or_Qualifier 1400 1416	altamente eficaz
R2	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T54	
T55	Neg_cue 140 142	no
T56	Quantifier_or_Qualifier 143 153	infecciosa
A12	Assertion T56 Negated
#41	AnnotatorNotes T56	C1550587; infectious - Entity Risk; Qualitative Concept
R3	Negation Arg1:T55 Arg2:T56	
T57	Quantifier_or_Qualifier 338 348	infecciosa
A13	Assertion T57 Negated
#42	AnnotatorNotes T57	C1550587; infectious - Entity Risk; Qualitative Concept
T58	Neg_cue 335 337	no
R4	Negation Arg1:T58 Arg2:T57	
T59	Neg_cue 408 410	no
T60	Quantifier_or_Qualifier 411 421	infecciosa
A14	Assertion T60 Negated
#43	AnnotatorNotes T60	C1550587; infectious - Entity Risk; Qualitative Concept
R5	Negation Arg1:T59 Arg2:T60	
R6	Overlap Arg1:T2 Arg2:T33	
R7	Experiences Arg1:T34 Arg2:T1	
R8	Experiences Arg1:T34 Arg2:T3	
R9	Has_Duration_or_Interval Arg1:T3 Arg2:T35	
R10	Experiences Arg1:T34 Arg2:T14	
T61	Observation 176 189	tolerado bien
A15	Status T61 History_of
R11	Experiences Arg1:T34 Arg2:T61	
R12	Overlap Arg1:T61 Arg2:T14	
R13	Overlap Arg1:T1 Arg2:T61	
R14	Used_for Arg1:T7 Arg2:T5	
R15	Experiences Arg1:T37 Arg2:T7	
R16	Experiences Arg1:T37 Arg2:T6	
R17	Has_Duration_or_Interval Arg1:T6 Arg2:T38	
R18	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T57	
R19	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T56	
R20	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T60	
R21	Has_Duration_or_Interval Arg1:T8 Arg2:T40	
R22	Has_Age Arg1:T39 Arg2:T43	
R23	Has_Age Arg1:T39 Arg2:T36	
R24	Has_Age Arg1:T42 Arg2:T43	
R25	Has_Age Arg1:T42 Arg2:T36	
R26	Overlap Arg1:T44 Arg2:T43	
R27	Overlap Arg1:T44 Arg2:T36	
T62	Quantifier_or_Qualifier 555 565	completado
R29	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T51	
R30	Overlap Arg1:T9 Arg2:T41	
T63	CONC 601 626	periodo doble enmascarado
R31	Has_Quantifier_or_Qualifier Arg1:T63 Arg2:T62	
#44	AnnotatorNotes T62	C1556117; completed - ManagedParticipationStatus; Idea or Concept
T64	CONC 646 678	extensión del periodo en abierto
R28	Has_Quantifier_or_Qualifier Arg1:T64 Arg2:T62	
T65	CONC 700 728	periodo de doble enmascarado
T66	CONC 731 749	periodo en abierto
R32	Has_Quantifier_or_Qualifier Arg1:T65 Arg2:T62	
R33	Has_Quantifier_or_Qualifier Arg1:T66 Arg2:T62	
T67	PROC 839 852	uso compasivo
#45	AnnotatorNotes T67	C2718016; Compassionate Use; Health Care Activity
R34	Used_for Arg1:T11 Arg2:T67	
T68	Observation 861 890	participación en los estudios
A16	Status T68 History_of
#46	AnnotatorNotes T68	C1278516; Patient participation status; Finding (?)
R35	After Arg1:T11 Arg2:T68	
T69	Observation 905 912	Capaces
#47	AnnotatorNotes T69	C1299581; Able (finding); Finding (?) | C1555472; Authorized; Finding (?)
R37	Overlap Arg1:T69 Arg2:T27	
R38	Used_for Arg1:T12 Arg2:T27	
R39	Overlap Arg1:T12 Arg2:T46	
R40	After Arg1:T27 Arg2:T28	
R41	Used_for Arg1:T13 Arg2:T28	
T70	Quantifier_or_Qualifier 927 934	primera
#48	AnnotatorNotes T70	C0205435; First (number); Quantitative Concept
R42	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T70	
T71	Quantifier_or_Qualifier 994 1000	última
#49	AnnotatorNotes T71	C1517741; Last; Qualitative Concept
R43	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T71	
T72	Quantifier_or_Qualifier 1088 1094	última
#50	AnnotatorNotes T72	C1517741; Last; Qualitative Concept
R44	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T72	
R45	Used_for Arg1:T15 Arg2:T29	
R46	Overlap Arg1:T15 Arg2:T47	
R47	Experiences Arg1:T48 Arg2:T29	
T73	Observation 1250 1277	estables oftalmológicamente
R48	Experiences Arg1:T48 Arg2:T73	
R49	Overlap Arg1:T45 Arg2:T73	
R50	Experiences Arg1:T50 Arg2:T53	
T74	Observation 1354 1362	voluntad
#51	AnnotatorNotes T74	C0600109; Willing; Finding
R51	Overlap Arg1:T74 Arg2:T16	
R52	Experiences Arg1:T50 Arg2:T16	
T75	Observation 1484 1518	retirada prematura de los estudios
A17	Status T75 History_of
#52	AnnotatorNotes T75	C0422727; Patient withdrawn from trial; Finding (?)
R55	Causes Arg1:T31 Arg2:T21	
R56	Causes Arg1:T31 Arg2:T22	
R57	Used_for Arg1:T23 Arg2:T31	
T76	Quantifier_or_Qualifier 1623 1628	grave
#53	AnnotatorNotes T76	C1547227; Severe - Severity of Illness Code; Intellectual Product
R58	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T76	
A18	Status T76 History_of
T77	PROC 1717 1724	estudio
A19	Status T77 History_of
#54	AnnotatorNotes T77	C0008976; Clinical Trials; Research Activity
R59	Overlap Arg1:T21 Arg2:T77	
R60	Overlap Arg1:T22 Arg2:T77	
R61	Overlap Arg1:T31 Arg2:T77	
R62	Causes Arg1:T30 Arg2:T21	
R63	Causes Arg1:T24 Arg2:T21	
R64	Causes Arg1:T30 Arg2:T22	
R65	Causes Arg1:T24 Arg2:T22	
R66	Used_for Arg1:T30 Arg2:T31	
R67	Used_for Arg1:T24 Arg2:T31	
T78	Quantifier_or_Qualifier 1801 1807	activa
#55	AnnotatorNotes T78	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R68	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T78	
T79	PROC 1150 1158	estudios
A20	Status T79 History_of
#56	AnnotatorNotes T79	C0008976; Clinical Trials; Research Activity
R70	Before Arg1:T79 Arg2:T45	
R71	Before Arg1:T29 Arg2:T45	
#57	AnnotatorNotes T61	C5684674; patient tolerated procedure well; Finding
R36	Experiences Arg1:T48 Arg2:T45	
R53	Experiences Arg1:T39 Arg2:T44	
R54	Experiences Arg1:T42 Arg2:T44	
#58	AnnotatorNotes T19	C1444604; Infective uveitis; Disease or Syndrome
A21	Experiencer T34 Patient
A22	Experiencer T37 Patient
A23	Experiencer T42 Patient
A24	Experiencer T39 Patient
A25	Experiencer T48 Patient
A26	Experiencer T49 Other
A27	Experiencer T50 Patient
